Company / Cost of Revenue
PLUS THERAPEUTICS, INC. Cost of Revenue History
FY2011-FY2018 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Cost of Revenue
$1.3M
FY2018
5-year range
$1.3M / $3.2M
FY2014-FY2018
Trend
-
vs FY2017
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Cost of Revenue has declined for 3 consecutive years, from $4M in FY2014 to $1M in FY2018.
Based on SEC 10-K filings.
$1M in FY2018 with a 5-year CAGR of -19.2%.
Improved from $3M to $1M over the past 3 years.
Cost of Revenue over time
Growth rates
- 3-Year CAGR
- -27.2%
- 5-Year CAGR
- -19.2%
- 10-Year CAGR
- -
Key checks
Key Insights
- 5-year CAGR of -19.2%, indicating a declining trend.
- Peak cost of revenue was recorded in FY2014.
Company context
Key Data Points
- Altman Z-Score -2.46 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Cost of RevenueValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | - | - |
| FY2024 | - | - |
| FY2018 | $1.3M | - |
| FY2017 | - | - |
| FY2016 | $3.2M | -6.9% |
| FY2015 | $3.4M | -14.5% |
| FY2014 | $4.0M | +4.2% |
| FY2013 | $3.8M | -1.8% |
| FY2012 | $3.9M | +15.1% |
| FY2011 | $3.4M | - |
As of FY2018 · SEC 10-K · Updated Jun 28, 2026